CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced plans to initiate a Phase 3 cardiovascular outcomes trial (CVOT) ...
Pegozafermin is ETNB’s long-acting FGF21 analog. It’s undergoing three Phase 3 trials. Two of those late-stage trials are for MASH (F2-F4), and the third is for severe hypertriglyceridemia. Also, ETNB ...
Retatrutide met primary and key secondary endpoints in a 2339-participant, randomized, double-blind, placebo-controlled phase 3 trial, demonstrating clinically meaningful weight reduction across 4, 9, ...
当前正在显示可能无法访问的结果。
隐藏无法访问的结果